Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global Use
Barbara Bolgiano,Eilís Moran,Nicola J Beresford,Fang Gao,Rory Care,Trusha Desai,Ida Karin Nordgren,Timothy R Rudd,Ian M Feavers,Prashant Bore,Sushil Patni,Vinay Gavade,Asha Mallya,Sameer Kale,Pankaj Sharma,Sunil K Goel,Sunil Gairola,Suhas Hattarki,Nikhil Avalaskar,Annamraju D Sarma,Marc LaForce,Neil Ravenscroft,Lakshmi Khandke,Mark R Alderson,Rajeev M Dhere,Sambhaji S Pisal
DOI: https://doi.org/10.3390/pathogens10080928
IF: 3.7
2021-07-23
Pathogens
Abstract:Towards achieving the goal of eliminating epidemic outbreaks of meningococcal disease in the African meningitis belt, a pentavalent glycoconjugate vaccine (NmCV-5) has been developed to protect against Neisseria meningitidis serogroups A, C, Y, W and X. MenA and X polysaccharides are conjugated to tetanus toxoid (TT) while MenC, Y and W polysaccharides are conjugated to recombinant cross reactive material 197 (rCRM197), a non-toxic genetic variant of diphtheria toxin. This study describes quality control testing performed by the manufacturer, Serum Institute of India Private Limited (SIIPL), and the independent control laboratory of the U.K. (NIBSC) on seven clinical lots of the vaccine to ensure its potency, purity, safety and consistency of its manufacturing. In addition to monitoring upstream-manufactured components, samples of drug substance, final drug product and stability samples were evaluated. This paper focuses on the comparison of the vaccine's critical quality attributes and reviews key indicators of its stability and immunogenicity. Comparable results were obtained by the two laboratories demonstrating sufficient levels of polysaccharide O-acetylation, consistency in size of the bulk conjugate molecules, integrity of the conjugated saccharides in the drug substance and drug product, and acceptable endotoxin content in the final drug product. The freeze-dried vaccine in 5-dose vials was stable based on molecular sizing and free saccharide assays. Lot-to-lot manufacturing consistency was also demonstrated in preclinical studies for polysaccharide-specific IgG and complement-dependent serum bactericidal activity for each serogroup. This study demonstrates the high quality and stability of NmCV-5, which is now undergoing Phase 3 clinical trials in Africa and India.